A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors

Category Primary study
JournalJournal of Clinical Oncology
Year 2020
This article has no abstract
Epistemonikos ID: 7beb46db7d63f6bcd7b7f54cdc2dd1b47ae7140e
First added on: Feb 12, 2025